Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) Cash & Equivalents (2016 - 2025)

Cellectis (CLLS) has 7 years of Cash & Equivalents data on record, last reported at $93.2 million in Q4 2022.

  • For Q4 2022, Cash & Equivalents fell 49.79% year-over-year to $93.2 million; the TTM value through Dec 2022 reached $93.2 million, down 49.79%, while the annual FY2022 figure was $93.2 million, 49.79% down from the prior year.
  • Cash & Equivalents reached $93.2 million in Q4 2022 per CLLS's latest filing, down from $185.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $451.5 million in Q4 2018 and bottomed at $93.2 million in Q4 2022.
  • Average Cash & Equivalents over 4 years is $242.9 million, with a median of $213.4 million recorded in 2020.
  • Peak YoY movement for Cash & Equivalents: soared 76.11% in 2018, then plummeted 49.79% in 2022.
  • A 4-year view of Cash & Equivalents shows it stood at $451.5 million in 2018, then plummeted by 46.59% to $241.1 million in 2020, then decreased by 23.02% to $185.6 million in 2021, then tumbled by 49.79% to $93.2 million in 2022.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $93.2 million in Q4 2022, $185.6 million in Q4 2021, and $241.1 million in Q4 2020.